🔍

Dr Agarwals Eye Hospital Ltd (526783)

📊 BSE: 526783 🏢 Hospital 📢 Latest filing: 05 Oct 2026 📝 Analysis written: 13 Nov 2025

Latest quarterly results (Q1 FY27)

In its latest reported quarter, Q1 FY27, Dr Agarwals' revenue was ₹143 Cr (+22.2% year on year, +19.1% on the previous quarter), and net profit ₹23.4 Cr (+37.5% year on year); the operating margin was 30.3%.

Q1 FY27 (₹ Cr)	Value	YoY vs Q1 FY26	QoQ
Revenue	₹143	+22.2%	+19.1%
Operating profit	₹43.3	+16.9%	+27.2%
Net profit	₹23.4	+37.5%	+46.1%
EPS (₹)	48.38	+31.8%	+44.0%
Operating margin	30.3%	—	—

Full quarterly financials → Results calendar →

📢 Recent Corporate Announcements

NCLT Chennai Sanctions Scheme of Amalgamation of Dr. Agarwal's Eye Hospital into AHCL

🟢 POSITIVE ⭐ 9/10

M&A 📅 05 Oct 2026, 10:51 PM

The Hon'ble NCLT Chennai bench has sanctioned the Scheme of Amalgamation of Dr. Agarwal's Eye Hospital Limited (AEHL) into Dr. Agarwal's Health Care Limited (AHCL). The order was pronounced on September 30, 2026, and uploaded on October 05, 2026. The scheme will have an Appointed Date of April 01, 2026, and will become operative upon completion of conditions in Clause 24. With AEHL having a market cap of ₹2,523 crore and TTM revenue of ₹497 crore, this amalgamation will consolidate the hospital business into the parent entity.

NCLT Chennai sanctioned the amalgamation of AEHL into AHCL in order pronounced on September 30, 2026
Sanction order officially uploaded on the NCLT website on October 05, 2026
Appointed Date of the scheme is confirmed as opening of business on April 01, 2026
Effective Date will be the first day of the calendar month following completion of Clause 24 conditions

💡 Track the announcement of the certified order copy, completion of Clause 24 conditionalities, the fixation of the Record Date, and the final Share Exchange Ratio details.

Dr Agarwals Eye Hospital Launches World's First Pinhole Pupilloplasty Centre in Chennai

🟢 POSITIVE ⭐ 4/10

EXPANSION 📅 27 Aug 2026, 03:39 PM

Dr Agarwals Eye Hospital Limited has launched the world's first dedicated Pinhole Pupilloplasty (PPP) Centre at its flagship facility in Alwarpet, Chennai. The proprietary microsurgical technique, developed by Dr. Amar Agarwal, has treated over 5,000 patients to date without requiring donor corneal tissue. The facility will combine clinical treatment, advanced diagnostics, research, and annual training for more than 50 ophthalmologists. While financial outlay and revenue projections were not disclosed, the launch strengthens the hospital's clinical differentiation in high-end ophthalmic care.

Launched the World's First dedicated Pinhole Pupilloplasty (PPP) Centre at flagship facility in Alwarpet, Chennai
Over 5,000 patients have received vision through the proprietary PPP procedure to date
More than 50 ophthalmologists are trained annually through workshops and academic programmes on this technique
Inaugurated on August 27, 2026, coinciding with the 41st National Eye Donation Fortnight

💡 Track whether specialized surgical service additions contribute to higher average revenue per occupied bed (ARPOB) or improved realization per procedure in upcoming quarterly earnings reports.

Dr Agarwals Eye Hospital Sets Sep 2 Record Date for ₹4/Share Final Dividend; AGM on Sep 9

🟡 NEUTRAL ⭐ 4/10

DIVIDEND 📅 14 Aug 2026, 06:45 PM

Dr. Agarwal's Eye Hospital has scheduled its 32nd Annual General Meeting for September 09, 2026, via video conferencing. The company confirmed a final dividend recommendation of ₹4.00 per share (40%) for FY26 across 48,32,827 equity shares, totaling a payout of ₹1.93 crore. The record date to determine shareholder eligibility is September 02, 2026, with dividend payment scheduled on or before October 08, 2026. The meeting will also consider special resolutions regarding revised remuneration packages for executive promoter directors.

32nd AGM scheduled for Wednesday, September 09, 2026, via Video Conferencing
Final dividend of ₹4.00 per equity share (40%), aggregating to a total cash outflow of ₹193.31 lakh
Record date for dividend entitlement fixed as September 02, 2026
Dividend payment date finalized on or before October 08, 2026, subject to shareholder approval
Shareholder voting sought on revised remuneration for CMD Dr. Amar Agarwal and WTD Dr. Athiya Agarwal

💡 Track the September 02, 2026 record date for dividend eligibility and monitor shareholder voting results on director remuneration resolutions post-AGM.

Dr. Agarwal's Eye Hospital Submits FY26 Annual Report; 32nd AGM on Sept 9, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 14 Aug 2026, 06:38 PM

Dr. Agarwal's Eye Hospital Limited has submitted its Annual Report for FY 2025-26 and scheduled its 32nd AGM for September 09, 2026. As per the report, FY26 total income reached ₹476.69 crore compared to ₹402.24 crore in FY25, while net profit grew to ₹70.10 crore from ₹54.65 crore with an EBITDA margin of 32.00%. The Chairman highlighted operational expansion in Tamil Nadu and prior shareholder approval for the merger integration with Dr. Agarwal's Health Care Limited.

FY26 Total Income rose to ₹476.69 crore compared to ₹402.24 crore in FY25
FY26 PAT reached ₹70.10 crore (14.71% margin) vs ₹54.65 crore in FY25
EBITDA for FY26 grew to ₹151.13 crore, delivering a 32.00% margin
Net worth expanded to ₹346.30 crore as of March 31, 2026, from ₹209.61 crore in FY25
32nd AGM scheduled for September 09, 2026, conducted via Video Conferencing

💡 Track voting resolutions and outcomes at the September 09, 2026 AGM, alongside further statutory updates regarding the merger integration with Dr. Agarwal's Health Care Limited.

Dr Agarwals Eye Hospital Q1 FY27: Revenue up 22% to ₹143 Cr, PAT up 35% to ₹23 Cr

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 03 Aug 2026, 05:36 PM

Dr Agarwals Eye Hospital reported a strong performance for Q1 FY27, with revenue from operations growing 22.3% YoY to ₹142.97 Cr. Net profit surged 35.5% YoY to ₹23.38 Cr, supported by healthy EBITDA margins of 31.6%. The company has utilized ₹28.20 Cr of the ₹70 Cr raised via preferential allotment in late 2025 for its stated objectives, with the balance currently in debt mutual funds. Additionally, the board re-appointed M/s. B Y & Associates as Cost Auditors for FY 2026-27.

Revenue from operations increased 22.3% YoY to ₹142.97 Cr from ₹116.92 Cr
Net profit after tax grew 35.5% YoY to ₹23.38 Cr compared to ₹17.26 Cr
EBITDA for the quarter stood at ₹45.22 Cr, up 19.2% from ₹37.93 Cr in the previous year
Basic EPS improved significantly to ₹48.38 from ₹36.72 in the year-ago period
Company utilized ₹28.20 Cr out of ₹70 Cr raised through preferential issue as of June 30, 2026

💡 Investors should monitor the deployment of the remaining ₹41.8 Cr from the preferential issue into new hospital capacity and track if the company can maintain its 30%+ operating margins amidst rising employee and consultancy costs.

35% PAT Growth to ₹23.38 Cr in Q1 FY27; Revenue Up 22% YoY

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 03 Aug 2026, 05:33 PM

Dr Agarwals Eye Hospital reported a strong start to FY27 with revenue from operations growing 22.3% YoY to ₹142.97 Cr. Net profit for the quarter increased 35.5% YoY to ₹23.38 Cr, significantly outperforming the ₹17.26 Cr reported in Q1 FY26. EBITDA margins remained robust at 31.6%, although slightly lower than the 32.4% in the year-ago period. The company also reported that ₹28.20 Cr of the ₹70 Cr raised via preferential issue in late 2025 has been utilized, with the balance held in debt mutual funds.

Revenue from operations increased 22.3% YoY to ₹142.97 Cr from ₹116.92 Cr.
Net profit after tax rose 35.5% YoY to ₹23.38 Cr compared to ₹17.26 Cr in Q1 FY26.
EBITDA for the quarter stood at ₹45.22 Cr, representing a 31.6% margin.
Basic and Diluted EPS improved to ₹48.38 from ₹36.72 in the corresponding quarter last year.
₹28.20 Cr of the ₹70 Cr preferential allotment proceeds have been utilized as of June 30, 2026.

💡 Investors should monitor the deployment of the remaining ₹41.8 Cr in preferential issue proceeds for potential network expansion and observe if the company can maintain its 30%+ operating margins amidst rising consultancy and employee costs.

Dr Agarwals Q1 FY27: Net Profit up 35.5% YoY to ₹23.38 Cr; Revenue grows 22.3%

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 03 Aug 2026, 05:24 PM

Dr Agarwals Eye Hospital reported a strong start to FY27 with Q1 revenue from operations growing 22.3% YoY to ₹142.97 Cr. Net profit surged 35.5% YoY to ₹23.38 Cr, significantly outpacing revenue growth due to operational leverage. EBITDA for the quarter stood at ₹45.22 Cr, a 19.2% increase from ₹37.93 Cr in the previous year. The company also reported that it has utilized ₹28.20 Cr of the ₹70 Cr raised via preferential issue in September 2025, with the balance currently held in debt mutual funds.

Revenue from operations increased 22.3% YoY to ₹142.97 Cr from ₹116.92 Cr.
Net Profit after tax grew 35.5% YoY to ₹23.38 Cr compared to ₹17.26 Cr in Q1 FY26.
EBITDA reached ₹45.22 Cr for the quarter, up from ₹37.93 Cr in the year-ago period.
Basic and Diluted EPS rose to ₹48.38 from ₹36.72 in the corresponding quarter last year.
Utilized ₹28.20 Cr of the ₹70 Cr preferential allotment proceeds as of June 30, 2026.

💡 Watch for the deployment timeline of the remaining ₹41.8 Cr preferential issue proceeds and whether the current 31.6% EBITDA margin is sustainable as the company expands.

Board Meeting on Aug 03, 2026, to Approve Q1 FY27 Financial Results

🟡 NEUTRAL ⭐ 3/10

BOARD_MEETING 📅 28 Jul 2026, 06:46 PM

Dr Agarwals Eye Hospital has scheduled a board meeting for August 03, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026. The company reported a TTM revenue of Rs 471 Cr and a PAT of Rs 69 Cr as of the previous quarter. Investors will be comparing these results against the June 2025 quarter, which saw a revenue of Rs 117 Cr and a net profit of Rs 17 Cr. The trading window for insiders remains closed until 48 hours after the results are published.

Board meeting scheduled for August 03, 2026, to approve Q1 FY27 results
Trading window closed until 48 hours after the announcement
Previous year's corresponding quarter (Jun 2025) revenue was Rs 117.0 Cr
Company maintains a healthy TTM Operating Profit Margin of 30.8%

💡 Monitor the financial results on August 03, 2026, to assess if the company can maintain its high operating margins (30.8%) and year-on-year revenue growth.

View All 526783 Announcements on Live Market Tracking →